2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-144313
    Galectin-3-IN-2 2883648-71-1 98%
    Galectin-3-IN-2 (Compound 9) is a potent multivalent inhibitor of galectin-3 (Gal-3; IC50=8.3 μM). Galectin-3 participates in many cancer-related metabolic processes.
    Galectin-3-IN-2
  • HY-144429
    TRPC5-IN-4 2762315-39-7 98%
    TRPC5-IN-4 is potent and safe TRPC inhibitor with IC50 value of 14.07 nM and 65 nM for TRPC5 and TRPC4, respectively. TRPC5-IN-4 shows no damage on the cellular component of liver and kidney. TRPC5-IN-4 can be used for the research of chronic kidney disease (CKD).
    TRPC5-IN-4
  • HY-144456
    Xanthine oxidase-IN-5 2276711-87-4 98%
    Xanthine oxidase-IN-5 is an effective and orally active xanthine oxidase (XO) inhibitor with IC50 value of 0.70 μM. Xanthine oxidase-IN-5 displays favorable agent-like properties with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 shows potent hypouricemic effects in hyperuricemic rat model.
    Xanthine oxidase-IN-5
  • HY-144713
    PTP1B-IN-16 2848581-86-0 98%
    PTP1B-IN-16 (Compound 46), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 12.6 μM. PTP1B-IN-16 can be used for the research of type 2 diabetes.
    PTP1B-IN-16
  • HY-144716
    PTP1B-IN-19 2848581-83-7 98%
    PTP1B-IN-19 (Compound 43), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 23.3 μM. PTP1B-IN-19 can be used for the research of type 2 diabetes.
    PTP1B-IN-19
  • HY-144717
    PTP1B-IN-18 2848581-84-8 98%
    PTP1B-IN-18 is an orally active complete mixed type protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 35.2 μM. PTP1B-IN-18 can be used for type 2 diabetes research.
    PTP1B-IN-18
  • HY-144718
    PTP1B-IN-17 2848581-85-9 98%
    PTP1B-IN-17 (Compound 45), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 30.2 μM. PTP1B-IN-17 can be used for the research of type 2 diabetes.
    PTP1B-IN-17
  • HY-14472S
    Tesofensine-d5 98%
    Tesofensine-d5 (NS-2330-d5) is the deuterium labeled Tesofensine (HY-14472). Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent. Tesofensine is a CNS acting anti-obesity agent.
    Tesofensine-d5
  • HY-144827
    AM8936 2820337-96-8 98%
    AM8936 acts as a balanced and potent cannabinoid receptor type-1 (CB1) agonist in functional assays (EC50s of 8.6 and 1.4 nM for rCB1 and hCB1, respectively). AM8936 exhibits high affinity for rat CB1 (rCB1) with Ki of 0.55 nM. AM8936 is a potent and efficacious CB1 agonist in vivo. AM8936 can be used for the research of CNS and metabolic disorders, pain, glaucoma, etc.
    AM8936
  • HY-14495A
    BMS-604992 free base 760944-56-7 98%
    BMS-604992 (EX-1314) free base is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 free base demonstrates high-affinity binding (ki=2.3 nM) and potent functional activity (EC50=0.4 nM). BMS-604992 free base can stimulate food intake in rodents.
    BMS-604992 free base
  • HY-14495B
    BMS-604992 dihydrochloride 1469750-46-6 98%
    BMS-604992 (EX-1314) dihydrochloride is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 dihydrochloride demonstrates high-affinity binding (ki=2.3 nM) and potent functional activity (EC50=0.4 nM). BMS-604992 dihydrochloride can stimulate food intake in rodents.
    BMS-604992 dihydrochloride
  • HY-145156
    CHU-128 2212020-93-2 98%
    CHU-128 is an effective and selective GLP-1R agonist. CHU-128 exhibits strong signal specificity and can activate the Gs/cAMP pathway, but it cannot activate the Gq/calcium signal, ERK phosphorylation, or recruit β-inhibitory proteins. CHU-128 can be used for research on type 2 diabetes.
    CHU-128
  • HY-14520B
    Tetrahydrofolic acid trihydrochloride 150731-85-4 98%
    Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) trihydrochloride is the biologically active vitamin B9 folate derivative. Tetrahydrofolic acid trihydrochloride is a donor of one-carbon groups for amino acids, nucleic acids, and lipids. Tetrahydrofolic acid trihydrochloride serves as an acceptor of free formaldehyde, producing 5,10-methylenetetrahydrofolate-Tetrahydrofolic acid.
    Tetrahydrofolic acid trihydrochloride
  • HY-145316
    Vanin-1-IN-2 2054952-13-3 98%
    Vanin-1-IN-2 is a potent vanin-1 inhibitor with an IC50 of 162 nM. Vanin-1 is a cell-surface-associated, glycosylphosphatidyl inositol (GPI)-anchored protein which is expressed at high levels in the kidney, liver, and small intestine.
    Vanin-1-IN-2
  • HY-145357
    SGLT1/2-IN-2 2387812-73-7 98%
    SGLT1/2-IN-2 demonstrates potent dual inhibitory activities (IC50 = 96 nM for SGLT1 and IC50 = 1.3 nM for SGLT2).
    SGLT1/2-IN-2
  • HY-145364
    Ghrelin receptor full agonist-2 2602452-73-1 98%
    Ghrelin receptor full agonist-2 (compound 12j) is a highly potent Ghrelin receptor full agonist.
    Ghrelin receptor full agonist-2
  • HY-145381
    11β-HSD1-IN-6 1303515-33-4 98%
    11β-HSD1-IN-6 is a an 11β-HSD-1 inhibitor. The 11β hydroxysteroid dehydrogenase enzymes (11β-HSDs) mediate the interconversion of the glucocorticoid (GC) corticosterone or cortisol to an inactive form, 11-dehydrocorticosterone (11-DHC) or Cortisone, respectively.
    11β-HSD1-IN-6
  • HY-145473
    1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PE 947381-58-0 98%
    1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PE (15(S)-HETE-SAPE) is a phospholipid containing stearic acid (HY-B2219) at the sn-1 position and 15(S)-HETE (HY-113336) at the sn-2 position. 1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PE is formed by direct oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PE (SAPE) by 15-LOX in human peripheral mononuclear cells activated with the calcium ionophore A23187 (HY-N6687).
    1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PE
  • HY-145490
    trans-Hydroxy Glimepiride 600177-94-4 98%
    trans-hydroxy Glimepiride is an active metabolite of the sulfonylurea Glimepiride (HY-B0104). It is formed from glimepiride primarily in the liver by the cytochrome P450 (CYP) isoform CYP2C9.
    trans-Hydroxy Glimepiride
  • HY-145503
    Decanoyl-L-carnitine chloride 369651-88-7 98%
    Decanoyl-L-carnitine chloride is an ester derivative of L-carnitine, which is an important cofactor of fatty acid metabolism.
    Decanoyl-L-carnitine chloride
Cat. No. Product Name / Synonyms Application Reactivity